Taking Aim at Melanoma

Antigen-presenting cells, such as macrophages or dendritic cells, elicit an immune response by displaying tumor antigens bound to the major histocompatibility complex (MHC) to circulating T-cells. Simultaneous T-cell recognition of glycoproteins CD80

By | April 1, 2011

JPG | PDF
Lucy Reading-Ikkanda" > Infographic: Boosting T Cell Activation
View full size JPG | PDF
Lucy Reading-Ikkanda

Antigen-presenting cells, such as macrophages or dendritic cells, elicit an immune response by displaying tumor antigens bound to the major histocompatibility complex (MHC) to circulating T-cells. Simultaneous T-cell recognition of glycoproteins CD80 and CD86 on the antigen-presenting cell is also necessary for activation of a T-cell response to antigens (1). After activation, the CTLA4 (cytotoxic T-lymphocyte-associated protein) gene is upregulated and acts to tamp down T-cell activity by binding to CD80/CD86 proteins on the surface of cells presenting antigens (2). The monoclonal antibody ipilimumab is designed to bind to CTLA4 on the surface of regulatory and helper T cells, where it blocks the inhibitory action of CTLA4 and enhances T-cell activity against tumors (3). The therapy has shown some success in patients who do not have BRAF mutations that can be specifically targeted.

 

Read the full story.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Athletes’ Microbiomes Differ from Nonathletes
  3. Stomach Cells Change Identity to Drive Precancerous State
  4. Mutation Linked to Longer Life Span in Men
AAAS